ImmunityBio logo

ImmunityBio

IBRX | NASDAQ
Chart Builder DCF Calculator
$5.98
-$0.04 (-0.66%)
At close: Nov 16, 2026, 4:00 PM ET
$5.93
-$0.05 (-0.84%)
After-hours: Nov 16, 2026, 7:52 PM ET
-0.66%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
50.7
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #271/1021 (Top 27%)

Key Statistics

Market Data

Market Cap $6.36B
1D Range
5.76 6.14
52W Range
1.98 11.55

Valuation (TTM)

PE -5.54
PB -5.55
EV/EBITDA -6.86

Valuation (NTM)

Forward PE 116.50
Forward PEG -0.03
Price Target $15.00
Loading financial charts...

Profile

ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to tre...

Sector Healthcare
Industry Biotechnology
Employees 688
IPO Date Jul 28, 2015
Fiscal Year January - December

Latest News

ImmunityBio, Inc. (IBRX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript

17 hours ago · seekingalpha.com

ImmunityBio, Inc. (IBRX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
New U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care

5 days ago · businesswire.com

New U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care
ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026

6 days ago · businesswire.com

ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026
IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18%

6 days ago · zacks.com

IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18%
Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy?

7 days ago · fool.com

Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy?
ImmunityBio Reports Wider Quarterly Loss

8 days ago · benzinga.com

ImmunityBio Reports Wider Quarterly Loss
ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue Estimates

8 days ago · zacks.com

ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue Estimates
ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million

8 days ago · businesswire.com

ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million
ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

8 days ago · businesswire.com

ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial

8 days ago · businesswire.com

ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial

Earnings

Latest Earnings
Nov 9, 2026
EPS
-$0.17
Miss -142.86%
REV
$48.84M
Miss -17.53%
Next Earnings
Feb 22, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
5
Consensus
Buy
Price Target
$15.00
Upside
+150.84%
Buy (5)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.